Pediatric neuro-Behçet's disease responsive to adalimumab.
Neurologic manifestations of Behçet's disease (neuro-Behçet's disease) are uncommon, but may cause patients significant morbidity and mortality. Neuro-Behçet's disease is chronic and may be refractory to treatment. We report on a 12-year-old girl with neuro-Behçet's disease that responded to standard doses of subcutaneous adalimumab.
Robinson
Angela Byun
AB
Division of Pediatric Rheumatology, Duke University Medical Center, Durham, North Carolina 27710, USA. rabin001@mc.duke.edu
Gallentine
William B
WB
Rabinovich
C Egla
CE
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001528:Behcet Syndrome / Q000473:pathology / Q000628:therapy*; D001921:Brain / Q000473:pathology*; D002648:Child; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab